Abstract: Systems and methods for identifying molecules that are biologically active against a disease, where the method can comprise culturing a first mammalian cell population under organoid formation conditions in the presence of a test molecule to obtain a first organoid, wherein the first mammalian cell population, when cultured under the organoid formation conditions in the absence of the test molecule, results in an organoid with a disease phenotype; imaging the first organoid following exposure to the test molecule; analyzing one or more images of the first organoid using a neural network that has been trained to assign a probability score of disease or non-disease ranging between 0% and 100%; assigning the first organoid a probability score ranging between 0% and 100%; wherein the test molecule is biologically active against the disease if the probability score of the first organoid is greater than a cutoff probability score of non-disease or lower than a cutoff probability score of disease.

Abstract: The present disclosure relates generally to compounds and methods for inhibiting the enzymatic activity of lysine demethylase 4 (KDM4) and treating cancer. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibiting lysine demethylase 4. Furthermore, the subject compounds and compositions are useful for the treatment of breast cancer and the like.

Abstract: The present invention is inter alia concerned with an inhibitor selected from the group consisting of a selective KMT9-inhibitor, a selective METTL21A-inhibitor and a selective METTL21B-inhibitor for use in the treatment of cancer. KMT9, METTL21A and METTL21B are characterized herein for the first time as histone methyl transferases, and inhibitors of the same can be used for treating cancer.

Abstract: A signal path definition element defining an ultrasonic signal path for ultrasonic signals transmitted and received by an ultrasonic flow meter is provided. The element includes two end reflection plates, a top reflection plate, and a plurality of support plates joining and positioning the two end reflection plates and the top reflection plate. Further, the end reflection plates, the top reflection plate, and the plurality of support plates are formed from a single stamped metal plate and folded such that the end reflection plates reflect ultrasonic signals between an ultrasonic signal transducer and the top reflection plate and the top reflection plate reflects ultrasonic signals between the end reflection plates.

Abstract: The present disclosure relates generally to compounds and methods for inhibiting the enzymatic activity of lysine demethylase 4 (KDM4) and treating cancer. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibiting lysine demethylase 4. Furthermore, the subject compounds and compositions are useful for the treatment of breast cancer and the like.

Abstract: Disclosed in the present application are: (i) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in therapy, (ii) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in treating cancer, in particular prostate cancer, and (iii) a method of screening for such a compound.

Abstract: The present invention relates to the use of a genetically modified non-human animal as an animal model for obesity or obesity-related disorders, wherein the amount of Lysine-specific Demethylase 1 (LSD1) in at least one tissue or at least one cell type of said animal is reduced.

Abstract: The present disclosure relates generally to compounds and methods for inhibiting the enzymatic activity of lysine demethylase 4 (KDM4) and treating cancer. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibiting lysine demethylase 4. Furthermore, the subject compounds and compositions are useful for the treatment of breast cancer and the like.

Abstract: Disclosed in the present application are: (i) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in therapy, (ii) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in treating cancer, in particular pro state cancer, and (iii) a method of screening for such a compound.

Abstract: Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal.

Abstract: The present invention relates to the use of a genetically modified non-human animal as an animal model for obesity or obesity-related disorders, wherein the amount of Lysine-specific Demethylase 1 (LSD1) in at least one tissue or at least one cell type of said animal is reduced.

Abstract: A kit is disclosed for installing a radio frequency transmitter assembly (30) in position for radio transmission and reception when connected to a water meter register (26, 40) that is situated below ground level, the kit comprising: a base member (22) for extending substantially horizontally from the meter register (26, 40); a transmitter assembly (30) having a transmitter body (32) for attachment to the base member (22) with the transmitter body in an upright position; an electrical cable (17) connected at one end to the meter register (26, 40) and connected at an opposite end to the transmitter assembly (30). The kit provides a product that can be installed in any one of three different configurations.

Abstract: Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal.

Abstract: The invention relates to the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to assay systems allowing to test LSD1 inhibitors for their ability to inhibit LSD1 function.

Abstract: A kit is disclosed for installing a radio frequency transmitter assembly (30) in position for radio transmission and reception when connected to a water meter register (26, 40) that is situated below ground level, the kit comprising: a base member (22) for extending substantially horizontally from the meter register (26, 40); a transmitter assembly (30) having a transmitter body (32) for attachment to the base member (22) with the transmitter body in an upright position; an electrical cable (17) connected at one end to the meter register (26, 40) and connected at an opposite end to the transmitter assembly (30). The kit provides a product that can be installed in any one of three different configurations.

Abstract: A water meter (10) and a flow control valve (30) are housed in a common pressure vessel (16), in which the flow control valve (30) restricts flow through a metering chamber (18) to less than the normal flow, while still permitting a flow sufficient for basic human needs, rather than completely interrupting supply of the utility, and in which the flow control valve (30) is controlled electrically through a control valve (40) in an energy efficient manner so as to utilize power from a self-contained power source (27) in another device (25) at the customer site (50).

Abstract: A sealed electronic meter register with no moving parts and no bottom wall or bottom cover includes a casing of plastic with an open bottom. A viewing window is snap fitted into a top wall of the casing. A gasket is placed on top of an electronic numerical display and under the viewing window. The display is placed on top of a frame that is positioned face down into the casing. An electronic circuit board with the processing circuitry of the device is attached to the bottom of the frame. A polyurethane compound sealing material is deposited though a hole in the circuit board and onto the backside of the display. An epoxy-resin sealant is then deposited from the bottom of the housing to seal over everything in the housing to protect the components and provide an exposed bottom surface for the assembly.

Abstract: A sealed electronic meter register with no moving parts and no bottom wall or bottom cover includes a casing of plastic with an open bottom. A viewing window is snap fitted into a top wall of the casing. A gasket is placed on top of an electronic numerical display and under the viewing window. The display is placed on top of a frame that is positioned face down into the casing. An electronic circuit board with the processing circuitry of the device is attached to the bottom of the frame. A polyurethane compound sealing material is deposited though a hole in the circuit board and onto the backside of the display. An epoxy-resin sealant is then deposited from the bottom of the housing to seal over everything in the housing to protect the components and provide an exposed bottom surface for the assembly.

Abstract: The present invention provides in vitro methods for detecting, grading or prognosticating cancer, in particular prostate cancer. The invention further provides isolated polynucleotides suitable for reducing or inhibiting the expression of protein kinase C beta I and/or II and/or alpha (and consequently the levels of histone H3 phosphorylated at threonine 6, histone H3 monomethylated at lysine 4, histone H3 dimethylated at lysine 4, histone H3 trimethylated at lysine 4) and further relates to pharmaceutical compositions comprising said polynucleotides for the treatment or prevention of cancer, in particular prostate cancer.